Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $199.5 million.

  • Tarsus Pharmaceuticals' Total Liabilities rose 4370.03% to $199.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.5 million, marking a year-over-year increase of 4370.03%. This contributed to the annual value of $152.5 million for FY2024, which is 12255.52% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Total Liabilities stood at $199.5 million, which was up 4370.03% from $162.4 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Total Liabilities ranged from a high of $199.5 million in Q3 2025 and a low of $10.7 million during Q1 2021
  • Moreover, its 5-year median value for Total Liabilities was $41.2 million (2023), whereas its average is $73.1 million.
  • In the last 5 years, Tarsus Pharmaceuticals' Total Liabilities plummeted by 50.75% in 2021 and then skyrocketed by 20243.7% in 2024.
  • Tarsus Pharmaceuticals' Total Liabilities (Quarter) stood at $12.2 million in 2021, then surged by 187.12% to $35.0 million in 2022, then soared by 95.93% to $68.5 million in 2023, then surged by 122.56% to $152.5 million in 2024, then surged by 30.84% to $199.5 million in 2025.
  • Its Total Liabilities stands at $199.5 million for Q3 2025, versus $162.4 million for Q2 2025 and $158.3 million for Q1 2025.